LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC [MA08.04]
(2021) 2020 World Conference on Lung Cancer — Location: Virtual (28.January.2021)
Files
2021_Riudavets_J_Thorac_Oncol_MA0804.pdf
Open Access - Adobe PDF
- 126.12 KB
Details
- Authors
- Abstract
- INTRODUCTION : The lung immune prognostic index (LIPI), which combines pretreatment derived neutrophils/[leukocytes minus neutrophils] ratio (dNLR) >3 and lactate dehydrogenase (LDH) > upper limit of normal (ULN), is associated with outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICI). We aimed to assess whether pretreatment LIPI correlates with durvalumab efficacy after concurrent chemoradiotherapy in the locally advanced setting.
- Affiliations
Citations
Riudavets, M., Mezquita, L., Auclin, E., Benitez, J. C., Le Pechoux, C., Majem, M., Dempsey, N., Lobefaro, R., Nadal, E., Amores, A., Menis, J., Tagliamento, M., López-Castro, R., Ponce, S., Bosch-Barrera, J., Aboubakar Nana, F., Mosquera, J., Pilotto, S., Reyes, R., et al. (2021). LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC [MA08.04]. Journal of Thoracic Oncology, 16(3), S161. https://doi.org/10.1016/j.jtho.2021.01.191 (Original work published 2021)